litlas
Log inCreate account

Joong‐Won Park

Active 1999–2025

Also published as
Joong-Won Park
80
Papers
22,006
Citations
55
h-index
80
i10-index

Citations

Citations per year for Joong‐Won Park1994: 3 citations1999: 1 citations2000: 3 citations2001: 2 citations2002: 5 citations2003: 8 citations2004: 3 citations2005: 12 citations2006: 13 citations2007: 10 citations2008: 21 citations2009: 34 citations2010: 15 citations2011: 24 citations2012: 47 citations2013: 48 citations2014: 123 citations2015: 133 citations2016: 113 citations2017: 156 citations2018: 202 citations2019: 939 citations2020: 1,201 citations2021: 1,329 citations2022: 1,132 citations2023: 893 citations2024: 1,312 citations2025: 616 citations2026: 7 citations1995–1998: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorChina: 2,171 citing papers, 23.8% of this breakdownUnited States: 1,429 citing papers, 15.7% of this breakdownJapan: 675 citing papers, 7.4% of this breakdownItaly: 594 citing papers, 6.5% of this breakdownGermany: 444 citing papers, 4.9% of this breakdownSouth Korea: 442 citing papers, 4.8% of this breakdownUnited Kingdom: 335 citing papers, 3.7% of this breakdownFrance: 330 citing papers, 3.6% of this breakdownTaiwan: 278 citing papers, 3.1% of this breakdownSpain: 276 citing papers, 3% of this breakdownHong Kong: 192 citing papers, 2.1% of this breakdownCanada: 188 citing papers, 2.1% of this breakdown
0%23.8%Other 19.3%

Institutions

Fields

  • Medicine78.3%
  • Biochemistry, Genetics and Molecular Biology15.5%
  • Immunology and Microbiology3.2%
  • Engineering0.9%
  • Chemistry0.4%
  • Computer Science0.3%
  • Other1.4%

Topics

  • Hepatocellular Carcinoma Treatment and Prognosis18.2%
  • Cholangiocarcinoma and Gallbladder Cancer Studies8.4%
  • Cancer Immunotherapy and Biomarkers5.2%
  • Liver Disease Diagnosis and Treatment5%
  • Cancer Mechanisms and Therapy4.5%
  • Liver physiology and pathology2.6%
  • Other56.1%

Coauthors

All papers

Open in search
  1. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial

    Authors: Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Fabio Piscaglia, Ari David Baron, Joong‐Won Park, Guohong Han, Jacek Jassem, Jean Frédéric Blanc, Arndt Vogel, Д. В. Комов, T.R. Jeffry Evans, Carlos López, Corina E. Dutcus, Matthew Guo, Kenichi Saito, Silvija Kraljevic, Toshiyuki Tamai, Min Ren, Ann‐Lii Cheng - The Lancet 2018 cited by 5,448

  2. Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

    Authors: Thomas Yau, Joong-Won Park, Richard S Finn, Ann-Lii Cheng, Philippe Mathurin, Julien Edeline, Masatoshi Kudo, James J Harding, Philippe Merle, Olivier Rosmorduc, Lucjan Wyrwicz, Eckart Schott, Su Pin Choo, Robin Kate Kelley, Wolfgang Sieghart, Eric Assenat, Renata Zaucha, Junji Furuse, Ghassan K Abou-Alfa, Anthony B El-Khoueiry, Ignacio Melero, Damir Begic, Gong Chen, Jaclyn Neely, Tami Wisniewski, Marina Tschaika, Bruno Sangro - The Lancet Oncology 2021 cited by 1,097

  3. Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma

    Authors: Ghassan K. Abou‐Alfa, Tim Meyer, Ann‐Lii Cheng, Anthony B. El-Khoueiry, Lorenza Rimassa, Baek‐Yeol Ryoo, İrfan Çiçin, Philippe Merle, Yen-Hsun Chen, Joong‐Won Park, Jean-Frederic Blanc, Luigi Bolondi, Heinz‐Josef Klümpen, Stephen L. Chan, Vittorina Zagonel, Tiziana Pressiani, Min-Hee Ryu, Alan P. Venook, Colin Hessel, Anne E. Borgman-Hagey, Gisela Schwab, Robin Kate Kelley - New England Journal of Medicine 2018 cited by 2,337

  4. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study

    Authors: Joong‐Won Park, Minshan Chen, M. Colombo, Lewis R. Roberts, Myron Schwartz, Pei‐Jer Chen, Masatoshi Kudo, Philip J. Johnson, Samuel Wagner, Lucinda Orsini, Morris Sherman - Liver International 2015 cited by 1,256

  5. Association of inflammatory biomarkers with clinical outcomes in nivolumab-treated patients with advanced hepatocellular carcinoma

    Authors: Bruno Sangro, Ignacio Melero, Samir Wadhawan, Richard S. Finn, Ghassan K. Abou‐Alfa, Ann‐Lii Cheng, Thomas Yau, Junji Furuse, Joong‐Won Park, Zachary Boyd, Hao Tang, Yun Shen, Marina Tschaika, Jaclyn Neely, Anthony B. El-Khoueiry - Journal of Hepatology 2020 cited by 421

  6. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma

    Authors: John Bridgewater, Peter R. Galle, Shahid A. Khan, Josep M. Llovet, Joong‐Won Park, Tushar Patel, Timothy M. Pawlik, Gregory J. Gores - Journal of Hepatology 2014 cited by 1,541

  7. EASL-ILCA Clinical Practice Guidelines on the management of intrahepatic cholangiocarcinoma

    Authors: Domenico Alvaro, Gregory J. Gores, Joël Walicki, Cesare Hassan, Gonzalo Sapisochín, Mina Komuta, Alejandro Forner, Juan W. Valle, Andrea Laghi, Sumera I. Ilyas, Joong‐Won Park, Robin Kate Kelley, María Reig, Bruno Sangro - Journal of Hepatology 2023 cited by 298

  8. Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.

    Authors: Peter R. Galle, Thomas Decaens, Masatoshi Kudo, Shukui Qin, Leonardo Fonseca, Bruno Sangro, Hatim Karachiwala, Joong‐Won Park, Edward Gane, Matthias Pinter, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Qi Wang, Caitlyn Stromko, Joseph Hreiki, Thomas Yau - Journal of Clinical Oncology 2024 cited by 146

  9. Molecular predictors of prevention of recurrence in HCC with sorafenib as adjuvant treatment and prognostic factors in the phase 3 STORM trial

    Authors: Roser Pinyol, Robert Montal, Laia Bassaganyas, Daniela Sia, Tadatoshi Takayama, Gar-Yang Chau, Vincenzo Mazzaferro, Sasan Roayaie, Han Chu Lee, Norihiro Kokudo, Zhongyang Zhang, Sara Torrecilla, Agrin Moeini, Leonardo Rodríguez‐Carunchio, Edward Gane, Chris Verslype, Adina Croitoru, Umberto Cillo, Manuel de la Mata, L. Lupo, Simone I. Strasser, Joong‐Won Park, Jordi Camps, Manel Solé, Swan N. Thung, Augusto Villanueva, Carol Peña, Gerold Meinhardt, Jordi Bruix, Josep M. Llovet - Gut 2018 cited by 335

  10. First-in-Human Phase I Study of Fisogatinib (BLU-554) Validates Aberrant FGF19 Signaling as a Driver Event in Hepatocellular Carcinoma

    Authors: Richard D. Kim, Debashis Sarker, Tim Meyer, Thomas Yau, Teresa Macarulla, Joong‐Won Park, Su Pin Choo, Antoine Hollebecque, Max W. Sung, Ho-Yeong Lim, Vincenzo Mazzaferro, Joerg Trojan, Andrew X. Zhu, Jung‐Hwan Yoon, Sunil Sharma, Zhong-Zhe Lin, Stephen L. Chan, Sandrine Faivre, Lynn G. Feun, Chia-Jui Yen, Jean‐François Dufour, Daniel H. Palmer, Josep M. Llovet, Melissa Manoogian, Meera Tugnait, Nicolas Stransky, Margit Hagel, Nancy E. Kohl, Christoph Lengauer, Cori Ann Sherwin, Oleg Schmidt‐Kittler, Klaus P. Hoeflich, Hongliang Shi, Beni B. Wolf, Yoon‐Koo Kang - Cancer Discovery 2019 cited by 250

  11. The role of hepatic resection in the treatment of hepatocellular cancer

    Authors: Sasan Roayaie, Ghalib Jibara, Parissa Tabrizian, Joong‐Won Park, Jijin Yang, Lünan Yan, Myron Schwartz, Guohong Han, Francesco Izzo, Mishan Chen, Jean‐Frédéric Blanc, Philip J. Johnson, Masatoshi Kudo, Lewis R. Roberts, Morris Sherman - Hepatology 2015 cited by 415

  12. APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy

    Authors: George Lau, Ming‐Lung Yu, Grace Lai–Hung Wong, Alexander Thompson, Hasmik Ghazinian, Jin-Lin Hou, Teerha Piratvisuth, Jidong Jia, Masashi Mizokami, Gregory Cheng, Guo-Feng Chen, Zhen-Wen Liu, Oidov Baatarkhuu, Ann‐Lii Cheng, Woon Leung Ng, Patrick Lau, Tony Mok, Jer-Ming Chang, Saeed Hamid, A. Kadir Dökmeci, Rino Alvani Gani, Diana A. Payawal, Pierce K. H. Chow, Joong‐Won Park, Simone I. Strasser, Rosmawaiti Mohamed, Khin Maung Win, Tanwandee Tawesak, Shiv Kumar Sarin, Masao Omata - Hepatology International 2021 cited by 171

  13. Proton beam radiotherapy vs. radiofrequency ablation for recurrent hepatocellular carcinoma: A randomized phase III trial

    Authors: Tae Hyun Kim, Young Hwan Koh, Bo Hyun Kim, Min Ju Kim, Ju Hee Lee, Boram Park, Joong‐Won Park - Journal of Hepatology 2020 cited by 217

  14. Orantinib versus placebo combined with transcatheter arterial chemoembolisation in patients with unresectable hepatocellular carcinoma (ORIENTAL): a randomised, double-blind, placebo-controlled, multicentre, phase 3 study

    Authors: Masatoshi Kudo, Ann‐Lii Cheng, Joong‐Won Park, Jae Hyung Park, Po‐Chin Liang, Hisashi Hidaka, Namiki Izumi, Jeong Heo, Youn Jae Lee, I‐Shyan Sheen, Chang‐Fang Chiu, Hitoshi Arioka, Satoshi Morita, Yasuaki Arai - ˜The œLancet. Gastroenterology & hepatology 2017 cited by 196

  15. Nivolumab plus ipilimumab versus lenvatinib or sorafenib as first-line treatment for unresectable hepatocellular carcinoma (CheckMate 9DW): an open-label, randomised, phase 3 trial

    Authors: Thomas Yau, Peter R. Galle, Thomas Decaens, Bruno Sangro, Shukui Qin, Leonardo Gomes da Fonseca, Hatim Karachiwala, Jean‐Frédéric Blanc, Joong‐Won Park, Edward Gane, Matthias Pinter, Ana Matilla Peña, Masafumi Ikeda, David Tai, Armando Santoro, Gonzalo Pizarro, Chang‐Fang Chiu, Michael Schenker, Aiwu Ruth He, Hong Jae Chon, Joanna Wójcik-Tomaszewska, Gontran Verset, Qi Qi Wang, Caitlyn Stromko, Jaclyn Neely, Prianka Singh, Maria Jesus Jimenez Exposito, Masatoshi Kudo - The Lancet 2025 cited by 270

  16. Overview of Asian clinical practice guidelines for the management of hepatocellular carcinoma: An Asian perspective comparison

    Authors: Yuri Cho, Bo Hyun Kim, Joong‐Won Park - Clinical and Molecular Hepatology 2023 cited by 75

  17. Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL Study

    Authors: Philip J. Johnson, Shukui Qin, Joong‐Won Park, Ronnie T.P. Poon, Jean‐Luc Raoul, Philip A. Philip, Chih‐Hung Hsu, Tsung‐Hui Hu, Jeong Heo, Jianming Xu, Ligong Lu, Yee Chao, Éveline Boucher, Kwang‐Hyub Han, Seung Woon Paik, Jorge Alberto Robles-Aviña, Masatoshi Kudo, Lünan Yan, Abhasnee Sobhonslidsuk, Д. В. Комов, Thomas Decaens, Won Young Tak, Long‐Bin Jeng, David Liu, Rana Ezzeddine, Ian Walters, Ann‐Lii Cheng - Journal of Clinical Oncology 2013 cited by 775

  18. Novel Model to Predict HCC Recurrence after Liver Transplantation Obtained Using Deep Learning: A Multicenter Study

    Authors: Joon Yeul Nam, Jeong‐Hoon Lee, Jun Ho Bae, Young Woon Chang, Yuri Cho, Dong Hyun Sinn, Bo Hyun Kim, Seong Hoon Kim, Nam‐Joon Yi, Kwang‐Woong Lee, Jong Man Kim, Joong‐Won Park, Yoon Jun Kim, Jung‐Hwan Yoon, Jae‐Won Joh, Kyung‐Suk Suh - Cancers 2020 cited by 71

  19. Sunitinib Versus Sorafenib in Advanced Hepatocellular Cancer: Results of a Randomized Phase III Trial

    Authors: Ann‐Lii Cheng, Yoon‐Koo Kang, Deng‐Yn Lin, Joong‐Won Park, Masatoshi Kudo, Shukui Qin, Hyun Cheol Chung, Xiangqun Song, Jianming Xu, Guido Poggi, Masao Omata, Susan Pitman Lowenthal, Silvana Lanzalone, Liqiang Yang, María José Lechuga, Éric Raymond - Journal of Clinical Oncology 2013 cited by 774

  20. Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: The phase III STAH trial

    Authors: Joong‐Won Park, Yoon Jun Kim, Do Young Kim, Si Hyun Bae, Seung Woon Paik, Youn Jae Lee, Hwi Young Kim, Han Chu Lee, Sang Young Han, Jae Youn Cheong, Oh Sang Kwon, Jong Eun Yeon, Bo Hyun Kim, Jaeseok Hwang - Journal of Hepatology 2018 cited by 202

  21. Brivanib in Patients With Advanced Hepatocellular Carcinoma Who Were Intolerant to Sorafenib or for Whom Sorafenib Failed: Results From the Randomized Phase III BRISK-PS Study

    Authors: Josep M. Llovet, Thomas Decaens, Jean‐Luc Raoul, Éveline Boucher, Masatoshi Kudo, Charissa Chang, Yoon‐Koo Kang, Eric Assénat, Ho-Yeong Lim, Valérie Boige, Philippe Mathurin, Lætitia Fartoux, Deng‐Yn Lin, Jordi Bruix, Ronnie T.P. Poon, Morris Sherman, Jean‐Frédéric Blanc, Richard S. Finn, Won Young Tak, Yee Chao, Rana Ezzeddine, David Liu, Ian Walters, Joong‐Won Park - Journal of Clinical Oncology 2013 cited by 596

  22. Merits and boundaries of the BCLC staging and treatment algorithm: Learning from the past to improve the future with a novel proposal

    Authors: Franco Trevisani, Alessandro Vitale, Masatoshi Kudo, Laura Kulik, Joong‐Won Park, David J. Pinato, Umberto Cillo - Journal of Hepatology 2024 cited by 77

  23. Overall survival and objective response in advanced unresectable hepatocellular carcinoma: A subanalysis of the REFLECT study

    Authors: Masatoshi Kudo, Richard S. Finn, Shukui Qin, Kwang‐Hyub Han, Kenji Ikeda, Ann‐Lii Cheng, Arndt Vogel, Francesco Tovoli, Kazuomi Ueshima, Hiroshi Aikata, Carlos López, Marc Pracht, Zhiqiang Meng, Bruno Daniele, Joong‐Won Park, D. Palmer, Toshiyuki Tamai, Kenichi Saito, Corina E. Dutcus, Riccardo Lencioni - Journal of Hepatology 2022 cited by 54

  24. A Prospective Evaluation of18F-FDG and11C-Acetate PET/CT for Detection of Primary and Metastatic Hepatocellular Carcinoma

    Authors: Joong-Won Park, Ji Hoon Kim, Seok Ki Kim, Keon Wook Kang, Kyung Woo Park, Jun-Il Choi, Woo Jin Lee, Chang‐Min Kim, Byung Ho Nam - Journal of Nuclear Medicine 2008 cited by 284